prompted diabetes experts such as Novo Nordisk and Eli Lilly to discontinue their ..... stigma. Diabetes giants such as Novo and Lilly have pulled their inhaled ..... causing diabetes experts such as Novo Nordisk NVO and Eli Lilly LLY to withdraw their
to continue supporting the dividend payments.Lilly has been steadily losing share in the insulin market because of Novo Nordisk 's more effective marketing and the success of its long-acting and rapid-acting insulin analogs.The patent loss
COPENHAGEN, Dec 3 (Reuters) - Denmark's Novo Nordisk has a stronger development pipeline of new drug candidates than it has ever had before, and thinks it can keep delivering the strong sales growth of the past decade, its chief executive said on Tuesday.
COPENHAGEN, Dec 3 (Reuters) - Denmark's Novo Nordisk , the world's biggest insulin producer, has a stronger pipeline of drug candidates than it has ever had before, its chief executive said on Tuesday.
COPENHAGEN, Dec 3 (Reuters) - Denmark's Novo Nordisk said it still expects to file its obesity drug candidate Liraglutide for regulatory review in the United States and the European Union around the turn of the year.
COPENHAGEN, Dec 3 (Reuters) - Denmark's Novo Nordisk said on Tuesday that a phase 3 trial of its diabetes drug IDegLira showed better control of blood sugar levels than its own long-acting insulin Tresiba.
Novo Nordisk ( NVO ) is set to initiate a Phase 2 study of oral Victoza . "It is a ..... t be easy, Thomsen says "the data [he has] so far suggests [ NVO ] can do it." NVO is looking to get the oral version to market within five to six years
COPENHAGEN, Nov 18 (Reuters) - NovoEight, a haemophilia drug made by Denmark's Novo Nordisk , is a step closer to marketing approval in Japan after it passed a review by the country's drugs committee.
By Sharon di Stefano : Clinical interest in oral insulin, estimated to have market potential upwards of $10 billion, is escalating as more diabetics are diagnosed each year and patients' petulant demands for an alternative to needles and pens use up more of a doctor's limited practice time. Not ...
The FDA approves Novo Nordisk 's ( NVO ) NovoRapid FlexTouch and Levemir FlexTouch prefilled insulin pens. The company plans to make the pens available in the U.S. "within the next year." ( PR ) Post your comment!